Publication: Cardiac complications in beta-thalassemia: From mice to men
Issued Date
2017-06-01
Resource Type
ISSN
15353699
15353702
15353702
Other identifier(s)
2-s2.0-85020291584
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Experimental Biology and Medicine. Vol.242, No.11 (2017), 1126-1135
Suggested Citation
Sirinart Kumfu, Suthat Fucharoen, Siriporn C. Chattipakorn, Nipon Chattipakorn Cardiac complications in beta-thalassemia: From mice to men. Experimental Biology and Medicine. Vol.242, No.11 (2017), 1126-1135. doi:10.1177/1535370217708977 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/41869
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Cardiac complications in beta-thalassemia: From mice to men
Other Contributor(s)
Abstract
© 2017, © 2017 by the Society for Experimental Biology and Medicine. Beta-thalassemia is an inherited hemoglobin disorder caused by reduced or absent synthesis of the beta globin chains of hemoglobin. This results in variable outcomes ranging from clinically asymptomatic to severe anemia, which then typically requires regular blood transfusion. These regular blood transfusions can result in an iron overload condition. The iron overload condition can lead to iron accumulation in various organs, especially in the heart, leading to iron overload cardiomyopathy, which is the major cause of mortality in patients with thalassemia. In the past decades, there is no doubt that the use of β-thalassemic mice as a study model to investigate the pathophysiology of iron overload cardiomyopathy and the role of various pharmacological interventions, has shed some light in understanding this serious complication and in improving the associated cardiac dysfunction. In this review, the effects that iron overload has on the hearts of β-thalassemic mice under conditions of iron overload as well as the efficacy of pharmacological interventions to combat these adverse effects on the heart are reviewed and discussed. The in-depth understanding of biomolecular alterations in the heart of these iron overload thalassemic mice will help give guidance for more effective therapeutic approaches in the near future. Impact statement: Iron overload cardiomyopathy is a major cause of morbidity and mortality in patients with thalassemia. Since investigation of iron overload cardiomyopathy in thalassemia patients has many limitations, a search for an animal model for this condition has been ongoing for decades. In the past decades, there is no doubt that the use of β-thalassemic mice as a study model to investigate the pathophysiology of iron overload cardiomyopathy and the role of various pharmacological interventions, has shed some light in understanding this serious complication and in improving the associated cardiac dysfunction. In this review, the effects of iron overload on the hearts of β-thalassemic mice under conditions of iron overload as well as the efficacy of pharmacological interventions to combat these adverse effects on the heart are reviewed and discussed.